- Sitravatinib plus tislelizumab in patients with metastatic non-small cell lung cancer (NSCLC)Zhou, Q.; Yu, X.; Gao, B.; Ma, Z.; Chu, Q.; Huang, D.; Zhao, J.; Day, D.; Body, A. L.; Pan, H.; Cui, J.; Li, H.; Sun, J.; Zhang, J.; Fei, C.; Wu, Y-L.ESMO Targeted Anticancer Therapies Congress (TAT), ELECTR NETWORK, 2022-03-07 To 2022-03-08.
- Safety, tolerability, and preliminary antitumor activity of sitravatinib plus tislelizumab (TIS) in patients (pts) with unresectable locally advanced or metastatic gastric cancer/gastroesophageal junction cancer (GC/GEJC)Chen, Zhendong; Bai, Yuxian; Zhang, Tao; Ying, Jieer; Lin, Xiaoyan; Yang, Liu; Wang, Jun; Zhang, Juan; Yu, Fan; Fei, Cong; Huang, Ruiqi; Li, JinASCO Gastrointestinal Cancers Symposium, San Francisco, CA, 2022-01-20 To 2022-01-22.被引 1
- Sintilimab versus pembrolizumab in monotherapy or combination with chemotherapy as first-line therapy for advanced non-small cell lung cancer: Results from phase 2, randomized clinical trial (CTONG1901).Liu, Si-Yang Maggie; Zhou, Qing; Yan, Hong-Hong; Bin, Gan; Yang, Ming-Yi; Deng, Jia-Yi; Tu, Hai-Yan; Zhang, Xuchao; Su, Jian; Yang, Jinji; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), ELECTR NETWORK, 2022-06-03 To 2022-06-07.被引 6
会议论文
Sitravatinib plus tislelizumab in patients with anti-PD-(L)1 refractory/resistant metastatic non-small cell lung cancer (NSCLC)
2被引10阅读
